Charles River bags new testing tech in $212M buyout

Charles River Laboratories has struck a deal to buy Celsis International for $212 million, nabbing its complementary bacterial detection systems for quality-control testing. "The acquisition of Celsis combines leading providers of endotoxin and bacterial testing and bacterial identification to establish EMD as a comprehensive provider of rapid quality control testing solutions across multiple industries," says Charles River CEO James Foster. "The acquisition nearly doubles the market opportunity for EMD testing products and services, offering access to the consumer products market in addition to our core biopharmaceutical market." More from FierceCRO